Skip to content

Clinical safety and efficacy of low dose RT-PA combined with Tirofiban in the treatment of acute non-cardiac cerebral infarction with unknown onset time of DWI-Flair mismatch

Clinical safety and efficacy of low dose RT-PA combined with Tirofiban in the treatment of acute non-cardiac cerebral infarction with unknown onset time of DWI-Flair mismatch

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029556
Enrollment
Unknown
Registered
2020-02-04
Start date
2020-02-07
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular disease

Interventions

Sponsors

Department of Neurology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2.The time that had elapsed since the patient was last known to be well had to be more than 4.5 hours; 3. Brain MRI showed that lesions on DWI were less than 1/3 of the blood supply area of the middle cerebral artery and there was no obvious signal change in FLAIR; 4. Diagnosis of ischemic stroke, a clear neurological deficit; 5. No previous patients with serious heart disease with ATRIAL fibrillation; 6. Admission NIHSS score < 15 points; 7. Brain CT has ruled out intracranial hemorrhage; 8. Family members signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Aged > 80 years; 2. Previous history of intracranial hemorrhage; 3. Symptoms suggest subarachnoid hemorrhage; 4. Existence of intracranial tumors, arteriovenous malformations or aneurysms; 5. Nearly 3 months have a history of severe head injury or cerebral infarction, but does not include the old small lacunar infarction Symptoms and signs; 6. Nearly a week difficult to oppress the site of hemostasis arterial puncture; 7. Severe liver and kidney dysfunction or severe diabetes; 8. Accompanied by active bleeding; 9. Blood glucose 185 mmHg or diastolic blood pressure> 110 mmHg; 10. Platelet count below normal; oral anticoagulant with INR> 1.7.

Design outcomes

Primary

MeasureTime frame
NIHSS score;mRS score three months after thrombolysis;symptomatic hemorrhage;Non-symptomatic hemorrhage;

Countries

China

Contacts

Public ContactLiang Zhigang

Department of Neurology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University

zgliang@hotmail.com+86 13723987720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026